Annovis Bio, Inc. (ANVS)
- Previous Close
1.5500 - Open
1.5600 - Bid 1.6500 x 900
- Ask 1.7300 x 800
- Day's Range
1.5600 - 1.7300 - 52 Week Range
1.1100 - 17.8800 - Volume
444,042 - Avg. Volume
386,488 - Market Cap (intraday)
33.127M - Beta (5Y Monthly) 1.45
- PE Ratio (TTM)
-- - EPS (TTM)
-2.3100 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
18.00
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
www.annovisbio.comRecent News: ANVS
View More
Performance Overview: ANVS
Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ANVS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ANVS
View MoreValuation Measures
Market Cap
30.20M
Enterprise Value
19.65M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.25
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-138.27%
Return on Equity (ttm)
-3,159.09%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-24.59M
Diluted EPS (ttm)
-2.3100
Balance Sheet and Cash Flow
Total Cash (mrq)
10.55M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-12.17M